Immunotherapy: Checkpoint barriers
Immunotherapy: Checkpoint barriers
复制标题
免疫疗法：检查点屏障
DOI：
10.1038/nrc.2016.118
复制
发表时间：
2016
影响因子：
78.5
通讯作者：
A. Dart
中科院分区：
文献类型：
--
作者：
A. Dart
两项研究揭示了影响黑色素瘤患者对抗细胞毒性T淋巴细胞相关抗原4（CTLA 4）治疗反应的遗传决定因素。使用全基因组测序，这些研究确定了可以预测反应的复发性突变。Riaz等人发现SERPINB 3和SERPINB 4的突变与抗CTLA 4治疗后的生存率相关。相比之下，Gao等人报道了干扰素-γ（IFNγ）途径基因的突变与对CTLA 4阻断的原发性抗性相关。这些发现强调了准确选择患者对免疫检查点阻断反应的重要性。
Two studies have uncovered genetic determinants that shape the response of patients with melanoma to anti-cytotoxic T lymphocyte associated antigen 4 (CTLA4) therapy. Using whole-genome sequencing, these studies identified recurrent mutations that could predict response. Riaz et al. found that mutations in SERPINB3 and SERPINB4 were associated with survival following anti-CTLA4 therapy. By contrast, Gao et al. reported that mutations in interferon-γ (IFNγ) pathway genes correlated with primary resistance to CTLA4 blockade. These findings underline the importance of accurate patient selection for responses to immune checkpoint blockade.